CAS No. : 195514-63-7

Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I002495
Synonyms:AP1903; Rimiducid;
Molecular Formula:C78H98N4O20
Molecular Weight:1411.63
IC50:0.1 nM (EC50, HT1080)
Price:Get quote
Inventory Status:In stock!
We would like to match the lowest price on market if possible.

Your information is safe with us.

Appearance:Semisolid (wax like)
Purity: > 98%
Cat No:I002495
Cas No:195514-63-7
IUPAC Name:[(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[[2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate

Rimiducid is a lipid-permeable tacrolimus analogue with homodimerizing activity. Dimerizer drug AP1903(cas 195514-63-7) homodimerizes an analogue of human protein FKBP12 (Fv) which contains a single acid substitution (Phe36Val) so that AP1903 binds to wild-type FKBP12 with 1000-fold lower affinity. This agent is used to homodimerize the Fv-containing drug-binding domains of genetically engineered receptors such as the iCD40 receptor of the autologous dendritic cell vaccine BP-GMAX-CD1, resulting in receptor activation.

1:J Clin Pharmacol. 2001 Aug;41(8):870-9. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers.Iuliucci JD,Oliver SD,Morley S,Ward C,Ward J,Dalgarno D,Clackson T,Berger HJ, PMID: 11504275
Abstract: AP1903 is a novel gene-targeted drug that is being developed for use in drug-regulated cell therapies. An intravenous, single-blind, placebo- and saline-controlled, ascending-dose study was performed to evaluate the safety, tolerability, and pharmacokinetics of AP1903. Twenty-eight normal healthy male volunteers were randomized into five dosage groups of AP1903 (0.01, 0.05, 0.1, 0.5, and 1 mg/kg). Within each group, 4 volunteers received a single dose of AP1903, 1 volunteer received an equal volume of placebo, and 1 received an equal volume of normal saline. The only exception was in the 0.5 mg/kg group, in which 4 volunteers were dosed: 3 received AP1903 and 1 received normal saline. All dosages were administered as intravenous infusions over 2 hours. Clinical safety parameters were monitored, and serial blood and urine samples were collected for analysis of AP1903. No drug-related adverse events were observed at any of the dose levels with the possible exception of facial flushing in 1 volunteer at the 1.0 mg/kg dose level. AP1903 plasma levels were directly proportional to the administered dose, with mean Cmax values ranging from approximately 10 to 1,275 ng/mL over the 0.01 to 1.0 mg/kg dose range. Following the infusion period, blood concentrations revealed a rapid distribution phase, with plasma levels being reduced to approximately 18%, 7%, and 1% of the maximal concentration at 0.5, 2, and 10 hours postdose, respectively. AP1903 was shown to be safe and well tolerated at all dose levels and demonstrated a favorable pharmacokinetic profile at doses well above the anticipated therapeutic dose.
Recommended Products
  • CAS No. :13645-43-7
    Product Name:


    Cat No: M127642 View details
  • CAS No. :146805-74-5
    Product Name:

    Methyl (2R)-2-fluoropropanoate

    Cat No: M127643 View details
  • CAS No. :149669-42-1
    Product Name:


    Cat No: M127644 View details
  • CAS No. :10561-89-4
    Product Name:

    1-Methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid

    Cat No: M127645 View details